跳到正文
原文
U.S. FDA· @FDA · X·· 7 天前AI 评分38
AI 导读

FDA肿瘤卓越中心与退伍军人事务研究机构签署新MOU,合作开展剂量优化、真实世界证据等工作,以更好服务退伍军人。首个项目已启动,研究DPYD基因变异如何影响结直肠癌退伍军人患者对化疗药5-氟尿嘧啶(5-FU)的体内代谢。

正文

This #VeteransDay, FDA's Oncology Center of Excellence & @VAResearch are teaming up with a new MOU. It supports collaboration on dose optimization, real-world evidence, & more — all to better serve #Veterans and protect public health. https://www.fda.gov/about-fda/oncology-center-excellence/oncology-center-excellence-and-department-veterans-affairs

The first project under this MOU is already underway! Researchers are studying how variants in the DPYD gene affect the body's processing of the chemotherapy drug 5-fluorouracil (5-FU) in veterans with colorectal cancer.

来源:U.S. FDA · x.com